Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Ryanair Holdings plc (RYAAY) Price & Performance

Amylx Pharmaceuticals IncTrade
Ryanair Holdings plcTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Ryanair Holdings plc trades at $60.24 (market cap $29.86B). The key difference: Ryanair Holdings plc is far larger — about 11.8× Amylx Pharmaceuticals Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXRYAAY
Market Cap
$2.53B$29.86B
Sector
HealthIndustrials
52-Week High
$24.19$73.82
52-Week Low
$7.82$53.24
Enterprise Value
$2.28B$26.83B
Dividend Yield
1.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Ryanair Holdings plc

RYAAY trades at $60.19, down 0.59% on the day, with a neutral technical signal and bearish moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and 22.41% ROE, supported by $13.95B revenue in 2025. Analyst sentiment is positive with a 62.5% buy rating, though recent news highlights pressure from lower fares and higher fuel costs.

The outlook for RYAAY is cautiously optimistic, with potential upside from industry consolidation and a strong balance sheet, but near-term risks include volatile fuel prices, competitive pricing pressure, and geopolitical tensions affecting travel demand. The stock's valuation at a P/E of 14.56 appears reasonable if earnings stabilize.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Ryanair Holdings plc

Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.

Read more on RYAAY